B+
Bull case
25%
Probability
Target price
$3.60
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
PALI
Palisade BioCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.90
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+59.5
Score
AI commentary
Sentiment is improved versus a pure financing-stress story because the 2025 equity raise removed near-term going-concern pressure and the April 2026 8-K tied new capital to Phase 2 enrollment preparation. Even so, forward visibility is still limited, the setup remains binary, and the deterministic prior stays negative, so this reads as a cautious monitoring name rather than a high-conviction bullish thesis [#8-K-2026-04-02] [#10-K-2026-03-20].
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-31catalystOperational follow-through from Iterative Health enrollment agreementHigh impact
Palisade said it hired Iterative Health to help expedite enrollment for the expected Phase 2 ulcerative colitis study and sold 1,536,885 shares to an Iterative affiliate for $3.0 million at $1.952 per share. Near-term disclosure that this support is translating into site activation or enrollment progress would help validate execution, while silence would keep the name in monitoring mode [#8-K-2026-04-02].
2026-06-30eventPlanned FDA IND submission for Phase 2 UC studyHigh impact
The 2025 10-K says management anticipates the Phase 1/1b UC program and exploratory FSCD cohort will support an FDA IND submission for a Phase 2 UC study in the second quarter of 2026. A clean regulatory step would improve visibility, but the same filing also states there is no assurance the FDA will accept the Canadian trial data or allow a U.S. Phase 2 to proceed [#10-K-2026-03-20].
2027-09-30catalystPhase 2 UC efficacy path for PALI-2108High impact
The 10-K says Palisade believes it has capital to fund operations through major clinical milestones, including a Phase 2 primary efficacy readout for PALI-2108 in UC expected in the second half of 2027. That is the main long-duration value inflection, but it remains a low-visibility, binary biotech setup before proof-of-concept [#10-K-2026-03-20].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology